{
    "name": "calcipotriene",
    "comment": "Rx",
    "other_names": [
        "Dovonex",
        "Calcitrene Ointment",
        "Sorilux"
    ],
    "classes": [
        "Antipsoriatics",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/dovonex-calcipotriene-topical-343541",
    "pregnancy": {
        "common": [
            "No data available on drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes in pregnant women exposed to calcipotriene",
            "Foam: Systemic exposure to calcipotriene is likely to be low"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, oral administration of calcipotriene to pregnant rats and rabbits during organogenesis resulted in an increased minor skeletal abnormalities, including enlarged fontanelles and extra ribs in rats and an increased incidence of minor skeletal abnormalities, including incomplete ossification of pubic bones and forelimb phalanges in rabbits"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of topically administered calcipotriene in human or animal milk, the effects on the breastfed infant, or the effects on milk production",
            "After topical administration, plasma concentrations of calcipotriene are low, and therefore, concentrations in human milk are likely to be low"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Hypercalcemia",
                "Evidence of vitamin D toxicity",
                "Topical use on the face"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypercalcemia and hypercalciuria reported with topical suspension; if hypercalcemia or hypercalciuria develop, discontinue treatment until parameters of calcium metabolism have normalized; incidence of hypercalcemia and hypercalciuria following topical suspension treatment of more than 8 weeks has not been evaluated",
                "For cream only: Allergic contact dermatitis has been observed with use of topical calcipotriene; such an observation should be corroborated with appropriate diagnostic patch testing"
            ],
            "specific": [
                {
                    "type": "Flammability",
                    "description": [
                        "Foam contains a flammable propellant; advise patients to avoid fire, flames, and smoking during and immediately following application"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Burning",
            "percent": null
        },
        {
            "name": "Itching",
            "percent": null
        },
        {
            "name": "Skin irritation",
            "percent": null
        },
        {
            "name": "Dermatitis",
            "percent": null
        },
        {
            "name": "Dry skin",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Peeling",
            "percent": null
        },
        {
            "name": "Worsening of psoriasis including facial",
            "percent": null
        },
        {
            "name": "scalp",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Folliculitis",
            "percent": null
        },
        {
            "name": "Hypercalcemia",
            "percent": null
        },
        {
            "name": "Hyperpigmentation",
            "percent": null
        },
        {
            "name": "Skin atrophy",
            "percent": null
        },
        {
            "name": "Contact dermatitis",
            "percent": null
        },
        {
            "name": "including allergic contact dermatitis",
            "percent": null
        }
    ]
}